Guardant Health (GH) is back in focus after the U.S. Food and Drug Administration approved its Guardant360 CDx liquid biopsy as a companion diagnostic for VEPPANU in ESR1 mutated advanced breast cancer.

Guardant Health’s latest FDA approval comes on the heels of a series of events, including a multi year collaboration with Nuvalent and first quarter results that paired higher sales with a wider net loss. It also follows a period where the share price has seen a 5.95% 7 day gain but a 9.32% year to date share price decline, alongside a 121.35% 1 year total shareholder return and a very large 3 year total shareholder return that suggests momentum has been strong over a longer horizon.

If this kind of precision oncology story has your attention, it could be worth scanning other healthcare focused AI opportunities using our curated screener for 35 healthcare AI stocks

With the stock up more than 120% over the past year but still trading below some implied value estimates, the key question now is whether Guardant Health is still undervalued or whether the market has already priced in its future growth.

Most Popular Narrative: 28.1% Undervalued

With Guardant Health closing at $92.26 versus a most followed fair value estimate of $128.33, the current price sits well below that narrative view of worth and anchors a bullish long term earnings and revenue path.

Accelerating adoption of non-invasive blood-based cancer diagnostics is driving substantial growth across Guardant Health's key product lines (Guardant360 Liquid, Reveal, and Shield). This is expanding the company's total addressable market and supporting high double-digit revenue growth, with continued strong volume momentum and share gains documented for both new and established oncology applications.

Want to see what is baked into that valuation gap? The narrative leans on rapid top line expansion, margin improvement and a punchy future earnings multiple that is usually reserved for market leaders.

Result: Fair Value of $128.33 (UNDERVALUED)

However, there are still clear pressure points, including heavy R&D spending and cash burn, as well as uncertainty around future reimbursement and payer adoption for key screening tests.

Another View: Rich Sales Multiple Raises Questions

The earlier narrative leans on a fair value of $128.33, yet the current P/S of 12.5x is far higher than both the US Healthcare industry at 1.2x and an estimated fair ratio of 5.4x. That is a wide gap. Is this a premium worth paying, or is valuation risk building in?

Next Steps

Sentiment appears divided, with strong growth hopes alongside real concerns about losses and execution risk. Consider acting promptly and reviewing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

Guardant Health might be front of mind today, but the market is full of other stocks that could suit your goals if you know where to look.

• Target potential mispricings by scanning a focused set of 51 high quality undervalued stocks that combine quality fundamentals with attractive entry points.
• Strengthen your income stream by reviewing 12 dividend fortresses that prioritize reliable, higher yielding payouts.
• Dial down portfolio stress by assessing 72 resilient stocks with low risk scores designed to keep risk scores in check while still aiming for sensible returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.